Shattuck Labs, Inc. (STTK)

Over the past six months, Shattuck Labs' stock price has been influenced by several events, including upgrades and increased price targets from analysts. Piper Sandler initiated coverage with an "Overweight" recommendation. The company launched a $75 million at-the-market offering and strategically shifted its focus from oncology to inflammatory bowel disorders, leading to a "Hold" rating from some analysts.

Shattuck Labs, Inc. does not experience demand seasonality in the traditional sense. The demand for its products is driven by the progression and success of its clinical trials, potential regulatory approvals, and the prevalence of the diseases it aims to treat.

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory and immune-mediated diseases. The company's primary focus has shifted from oncology to inflammatory bowel disorders, with its lead product candidate being SL-325, a potential first-in-class Death Receptor 3 (DR3) blocking antibody for IBD treatment. They are also developing SL-425 and multiple preclinical DR3-based bispecific antibodies.

Shattuck Labs, Inc. is headquartered in Austin, Texas, and has offices in Durham, North Carolina.

In the past year, Shattuck Labs has received a consensus "Hold" rating from analysts, with an average rating score of 2.43. MarketBeat evaluated Shattuck Labs as scoring higher than 67% of companies in the medical sector. A notable event impacting the company's reputation was its pivot from oncology to focus on inflammatory bowel disorders.

Shattuck Labs, Inc. has a diverse ownership structure, including institutional, retail, and individual investors. Major institutional owners include Orbimed Advisors LLC and Adage Capital Partners Gp, L.l.c., each holding 9.97% of the company. Hedge funds collectively own 27% of Shattuck Labs, and insiders own approximately 16.42% of the company's stock.